Claims
- 1. A method of treating FSD which method comprises administering to a patient in need of such treatment an effective amount of a compound that is an α1A and/or an α1L adrenergic receptor antagonist.
- 2. A method of claim 1, wherein the α1A and/or an α1L adrenergic receptor antagonist has a Ki in a binding assay of less than 100 nM, or a pA2 greater than 7 in a functional assay.
- 3. A method of claim 1, wherein the α1A and/or an α1L adrenergic receptor antagonist has a Ki in a binding assay of less than 10 nM, or a pA2 greater than 8 in a functional assay.
- 4. A method of claim 1, wherein the α1A and/or an α1L adrenergic receptor antagonist has a Ki in a binding assay of less than 1 nM, or a pA2 greater than 9 in a functional assay.
- 5. A method of claim 1, wherein the compound is a selective α1L and/or a selective α1A adrenergic receptor antagonist.
- 6. A method of claim 5, wherein the compound is more than 10-fold selective for α1L and/or α1A receptor over α1B receptor.
- 7. A method of claim 5, wherein the compound is more than 10-fold selective for α1L and/or α1A receptor over α1D receptor.
- 8. A method of claim 5, wherein the compound is more than 10-fold selective for α1L and/or α1A receptor over α1D and α1B receptors.
- 9. A method of claim 1, wherein FSD is FSAD and/or FOD.
- 10. A method of claim 1, wherein the compound is a compound of formula (I):
- 11. A method of claim 10, wherein the compound is selected from:
5-cyclopropyl-7-methoxy-2-(2-([dimethylamino]methyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(2-(1-pyrrolidinylmethyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(2-(4-morpholinylmethyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(5-([dimethylamino]methyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(5-(1-pyrrolidinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(5-(1-piperidinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(5-(4-morpholinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(5-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone; 5-cyclopropyl-7-methoxy-2-(2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or pharmaceutically acceptable salts or solvates thereof.
- 12. A method of claim 5, wherein the compound is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt or solvent thereof.
- 13. A method of claim 1, wherein the compound is selected from tamsulosin, doxazosin, terazosin, alfuzosin, or silodosin.
- 14. An intravaginal formulation comprising a compound as defined in claim 1.
- 15. A formulation as claimed in claim 14, which is a cream or a gel.
- 16. A method of enhancing sexual function in a female which method comprises administering to a healthy female an α1A and/or an α1L adrenergic receptor antagonist.
- 17. A method of screening for compounds useful for treating FSD, which method comprises screening compounds for antagonist activity against α1A and/or α1L adrenergic receptor, and selecting compounds with an Ki of less than 100 nM, or a pA2 greater than 7.
- 18. A method of treating or preventing FSD which method comprises administration of a combination comprising one or more α1A and/or an α1L adrenergic receptor antagonists, and one or more of the following auxiliary agents:
(a) A PDE5 inhibitor; (b) A neutral endopeptidase (NEP) inhibitor; (c) A Dopamine D3 receptor agonist; (d) A 5HT1A receptor agonist or a 5HT2C receptor agonist; (e) Agents used for hormone replacement therapy (HRT); and (f) Agents used in combination for HRT and additional androgen therapy.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0225908.3 |
Nov 2002 |
GB |
|
Parent Case Info
[0001] This application claims priority to U.S. Provisional Serial No. 60/429,729, filed Nov. 27, 2002, which claims priority to GB Application Serial No. 0225908.3, filed Nov. 6, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60429729 |
Nov 2002 |
US |